Adriamycin에 의해 유발된 가역적인 심근병증 1례

Abstract

Adriamycin is a chemotherapeutic agent highly effective against a wide range of neoplasms. A primary limiting factor to the administration of this drug is a cardiotoxicity, which frequently develops when the cumulative dose exceeds 500 mg/m2. Cardiomyopathy, which may develop even after a year of discontinuation of adriamycin therapy, is though to be rapidly progressive and unresponsive to standard cardiac therapy. We experienced a case of adriamycininduced cardiomyopathy. A 53-year-old male patient who received 337 mg/m2 of adriamycin experienced congestive heart failure at 5 years since the completion of the therapy. Endomyocardial biopsy showed vacuolization of myocytes and focal fibrotic areas. The patient responded to diuretics, inotrophic agents, and an angiotensin converting enzyme inhibitors, and resolution of left ventricular dysfunction was verified by plain chest radiography and echocardiography.